Drug Trial Radar · NCT00948766
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
Last checked: Nov 20, 2026Latest source record: Aug 28, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
716
Actual
Start
Jul 2009
Primary completion
Jan 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 29, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm\^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm\^2 patch) in patients with Severe Dementia of the Alzheimer's Type in a 24-week study. The extension study obtained additional safety and efficacy data, as well as provided the higher dose rivastigmine patch to all patients who completed the core study for an additional 24 weeks.
Conditions
- Alzheimer's Disease
Interventions
Rivastigmine 4.6 mg/24 h (5 cm^2)Drug
Rivastigmine was supplied in a 5 cm\^2 patch which released 4.6 mg/24 h. Patches were changed daily.
Rivastigmine 9.5 mg/24 h (10 cm^2)Drug
Rivastigmine was supplied in a 10 cm\^2 patch which released 9.5 mg/24 h. Patches were changed daily.
Rivastigmine 13.3 mg/24 h (15 cm^2)Drug
Rivastigmine was supplied in a 15 cm\^2 patch which released 13.3 mg/24 h. Patches were changed daily.
PlaceboDrug
Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24Time frame: Baseline of the core study to Week 24 of the core study
- Core Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24Time frame: Baseline of the core study to Week 24 of the core study
Locations
95 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Research Advantage Inc./Neurological. Physicians of Arizona, Inc
Tempe, Arizona
Northwest Neuro Specialist, PLLC
Tucson, Arizona
IHS Research Center Inc.
Conway, Arkansas
East Bay Physicians Medical Group
Berkeley, California
ATP Clinical Research, Inc.
Costa Mesa, California
Neuro Pain Medical Center
Fresno, California
Margolin Brain Institute
Fresno, California
Collaborative Neuroscience Network Inc.
Garden Grove, California
PCND Neuroscience Research Institute Inc./The Center for Memory and Aging
Poway, California
Anderson Clinical Research
Redlands, California
San Francisco Clinical Research Center
San Francisco, California
Neuropsychiatric Research Center of Orange County
Santa Ana, California
California Neuroscience Research Medical Group, Inc.
Sherman Oaks, California
Viking Clinical Research Center
Temecula, California
Collaborative Neuroscience Network, Inc
Torrance, California
Senior Care of Colorado
Aurora, Colorado
Clinical Research Studies Dept. of Clinical Science and Medical Education
Boca Raton, Florida
Quantum Laboratories Memory Disorder Center
Deerfield Beach, Florida
Brain Matters Research, Inc.
Delray Beach, Florida
Neurologic Consultants, PA
Fort Lauderdale, Florida
White-Wilson Medical Center
Fort Walton Beach, Florida
MD Clinical
Hallandale, Florida
Sunrise Clinical Research, Inc
Hollywood, Florida
Compass Research, LLC
Orlando, Florida
Integrity Research, LLC
Pensacola, Florida
Neurostudies, Inc.
Port Charlotte, Florida
Stedman Clinical Trials, LLC
Tampa, Florida
Center for Clinical Trials
Venice, Florida
Premiere Research Institute
West Palm Beach, Florida
Alexian Brothers Neuroscience Institute
Elk Grove Village, Illinois
Elkhart Clinic, LLC
Elkhart, Indiana
Indiana University Medical Center
Indianapolis, Indiana
University of Kansas Medical Center
Kansas City, Kansas
MidAmerica Neuroscience Reseach Institute
Lenexa, Kansas
Precise Clinical Research Solutions
Manhattan, Kansas
LSU Health Sciences Center/Department of Psychiatry Psychopharmacology Research Clinic
Shreveport, Louisiana
J. Gary Booker, MD APMC
Shreveport, Louisiana
Pharmasite Research
Baltimore, Maryland
The Samuel and Alexia Bratton Memory Clinic, William Hill Inc
Easton, Maryland
Neuroscience Research of the Berkshires
Pittsfield, Massachusetts
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.